• Explore /
  • Poster
  • / Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).

Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).

Abstract Poster

Authors

Valentina Guarneri

Valentina Guarneri

Department of Surgery, Oncology and Gastroenterology, University of Padua and Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy

Valentina Guarneri , Maria Vittoria Dieci , Giancarlo Bisagni , Daniele Giulio Generali , Katia Cagossi , Samanta Sarti , Antonio Frassoldati , Lorenzo Gianni , Luigi Cavanna , Graziella Pinotti , Antonino Musolino , Federico Piacentini , Andrea Michelotti , Saverio Cinieri , Gaia Griguolo , Federica Miglietta , Gian Luca De Salvo , Pier Franco Conte

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT00429299

Citation

J Clin Oncol 38: 2020 (suppl; abstr 582)

DOI

10.1200/JCO.2020.38.15_suppl.582

Abstract #

582

Poster Bd #

74

Abstract Disclosures

Similar Posters

First Author: Elisa Agostinetto

First Author: Sandra M. Swain

First Author: Emanuela Risi

First Author: Christian Eichler